Aurora Kinase

The Aurora kinases comprise a family of evolutionary conserved serine/threonine kinases (Aurora-A, Aurora-B, and Aurora-C). Aurora kinases control multiple events during cell cycle progression and are essential for mitotic and meiotic bipolar spindle assembly and function.

Aurora-A, Aurora-B, and Aurora-C share a highly conserved kinase domain but have quite different subcellular localizations and functions during mitosis. Aurora-A mostly controls centrosome maturation and bipolar spindle assembly, while Aurora-B and Aurora-C are required for condensation, attachment to kinetochores, and alignment of chromosomes during (pro-)metaphase and cytokinesis. In human tumors, all Aurora kinase members play oncogenic roles related to their mitotic activity and promote cancer cell survival and proliferation. Inhibitors targeting Aurora kinases have attracted attention in cancer research.

Aurora Kinase Inhibitors & Modulators

AAPK-25

Cat. No.: HY-126249

AAPK-25 is a potent and selective **Aurora/PLK** dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone $H3^{Ser10}$ phosphorylation and followed by a surge in apoptosis.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AKI603

Cat. No.: HY-123159

AKI603 is an inhibitor of **Aurora kinase A (AurA)**, with an IC_{50} of 12.3 nM. AKI603 is developed to overcome resistance mediated by BCR-ABL-T315I mutation. AKI603 exhibits strong anti-proliferative activity in leukemic cells.



Purity: 98.05%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Alisertib

(MLN 8237)

Cat. No.: HY-10971

Alisertib (MLN 8237) is an orally active and selective **Aurora A kinase** inhibitor (IC_{50}=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.



Purity: 99.84%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Alisertib sodium

(MLN 8237 sodium)

Cat. No.: HY-10971A

Alisertib (MLN 8237) sodium is an orally active and selective **Aurora A kinase** inhibitor (IC_{50}=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AMG 900

Cat. No.: HY-13253

AMG 900 is a potent and highly selective **pan-Aurora** kinases inhibitor with IC_{50} of 5 nM, 4 nM and 1 nM for **Aurora A**, **B** and **C**, respectively.



Purity: 99.29%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AT9283

Cat. No.: HY-50514

AT9283 is a multi-targeted kinase inhibitor with potent activity against **Aurora A/B**, **JAK2/3**, **Abl (T315I)** and **Flt3** (IC_{50}s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.



Purity: 99.70%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

Aurora A inhibitor 1

Cat. No.: HY-143713

Aurora A inhibitor 1 is a potent and selective inhibitor of **Aurora A**. Aurora A has been implicated in cancers of diverse histological origin and may possess oncogenic properties when overexpressed.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora A inhibitor 2

Cat. No.: HY-146037

Aurora A inhibitor 2 (Compound 16h) is a potent **Aurora A kinase** inhibitor with an IC_{50} of 21.94 nM. Aurora A inhibitor 2 induces caspase-dependent **apoptosis** in MDA-MB-231 cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora A/PKC-IN-1

Cat. No.: HY-144307

Aurora A/PKC-IN-1 (Compound 2e) is a potent dual inhibitor of **Aurora A (AurA)** and **PKC (α, β1, β2, and θ) kinases** with IC_{50}s of 6.9 nM and 16.9 nM for AurA and PKCα, respectively. Aurora A/PKC-IN-1 has antiproliferative activity in breast cancer cells and antimetastatic activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora B inhibitor 1

Cat. No.: HY-U00304

Aurora B inhibitor 1 is an **Aurora B** (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a K_i value of <0.010 uM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Aurora inhibitor 1

Cat. No.: HY-111506

Aurora inhibitor 1 is a potent **Aurora** inhibitor with an IC_{50} of ≤ 4 nM and ≤13 nM for **Aurora A** and **Aurora B** kinase, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora kinase inhibitor-2

Cat. No.: HY-112355

Aurora kinase inhibitor-2 is a selective and ATP-competitive **Aurora kinase** inhibitor with IC_{50}s of 310 nM and 240 nM for **Aurora A** and **Aurora B**, respectively.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Aurora kinase inhibitor-3

Cat. No.: HY-112373

Aurora kinase inhibitor-3 is a strong and selective **Aurora A kinase** inhibitor with an IC_{50} of 42 nM, and weakly inhibits EGFR with an IC_{50} of >10 μM.



Purity: 99.34%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Aurora kinase inhibitor-8

Cat. No.: HY-144991

Aurora kinase inhibitor-8 is a highly selective inhibitor of the **Aurora kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora kinase-IN-1

Cat. No.: HY-115932

Aurora kinase-IN-1 (Compound 9) is a potent inhibitor of **aurora kinase**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Aurora/LIM kinase-IN-1

Cat. No.: HY-144438

Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of **aurora** and **lim** kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Barasertib

(AZD1152)

Cat. No.: HY-10127

Barasertib (AZD1152), a pro-drug of Barasertib-hQPA, is a highly selective **Aurora B** inhibitor with an IC_{50} of 0.37 nM in a cell-free assay. Barasertib (AZD1152) induces growth arrest and apoptosis in cancer cells.



Purity: 98.95%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Barasertib-HQPA

(AZD2811; INH-34; AZD1152-HQPA)

Cat. No.: HY-10126

Barasertib-HQPA (AZD2811) is a highly selective **Aurora B** inhibitor with an IC_{50} of 0.37 nM in a cell-free assay. Barasertib-HQPA (AZD2811) induces growth arrest and apoptosis in cancer cells.



Purity: 99.47%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

BI-847325

Cat. No.: HY-18955

BI-847325 is an ATP competitive dual inhibitor of **MEK** and aurora kinases (**AK**) with IC_{50} values of 4 and 15 nM for human MEK2 and AK-C, respectively.



Purity: 98.66%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CCT 137690

Cat. No.: HY-10804

CCT 137690 is a potent and orally available **aurora** kinase inhibitor with IC_{50}s of 15, 25, and 19 nM for aurora A, B and C, respectively.



Purity: 99.10%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CCT129202

Cat. No.: HY-12049

CCT129202 is an **aurora** kinase inhibitor with IC_{50}s of 42, 198, and 227 nM for aurora A, B and C, respectively.



Purity: 98.24%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

CCT241736

Cat. No.: HY-18161

CCT241736 is a potent and orally bioavailable dual **FLT3** and **Aurora kinase** inhibitor, which inhibits Aurora kinases (Aurora-A K_d, 7.5 nM, IC_{50}, 38 nM; Aurora-B K_d, 48 nM), FLT3 kinase (K_d, 6.2 nM), and FLT3 mutants including FLT3-ITD (K_d, 38 nM) and FLT3(D835Y) (K_d, 14 nM).



Purity: 98.09%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

CD532

Cat. No.: HY-112273

CD532 is a potent **Aurora A kinase** inhibitor with an IC_{50} of 45 nM. CD532 has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN. CD532 also can directly interact with AURKA and induces a global conformational shift.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CD532 hydrochloride

Cat. No.: HY-112273A

CD532 hydrochloride is a potent **Aurora A kinase** inhibitor with an IC_{50} of 45 nM. CD532 hydrochloride has the dual effect of blocking Aurora A kinase activity and driving degradation of MYCN.



Purity: 99.31%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

Cenisertib

(AS-703569; R-763)

Cat. No.: HY-13072

Cenisertib (AS-703569) is an ATP-competitive multi-kinase inhibitor that blocks the activity of **Aurora-kinase-A/B, ABL1, AKT, STAT5 and FLT3**.



Purity: 99.64%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Chiauranib

(CS2164)

Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: 99.28%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CYC-116

Cat. No.: HY-10558

CYC-116 is a potent **aurora A** and **aurora B** inhibitor with K_is of 8 and 9 nM, respectively.



Purity: 98.17%
Clinical Data: Phase 1
Size: 10 mg, 50 mg, 100 mg

Danusertib

(PHA-739358)

Cat. No.: HY-10179

Danusertib is a pyrrolo-pyrazole and **aurora kinase** inhibitor with IC_{50} of 13, 79, and 61 nM for Aurora A, B, and C, respectively.



Purity: 99.44%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

dAURK-4

Cat. No.: HY-137344

dAURK-4, an Alisertib derivative, is a potent and selective **AURKA (Aurora A)** degrader. dAURK-4 has anticancer effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

dAURK-4 hydrochloride

Cat. No.: HY-137344A

dAURK-4 hydrochloride, an Alisertib derivative, is a potent and selective **AURKA (Aurora A)** degrader. dAURK-4 hydrochloride has anticancer effects.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Derrone

Cat. No.: HY-N3737

Derrone, a prenylated isoflavones, is an **Aurora kinase** inhibitor, with IC_{50} values of 6 and 22.3 μM against **Aurora B** and **Aurora A**, respectively. Derrone shows anti-tumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

ENMD-2076

Cat. No.: HY-10987A

ENMD-2076 is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 99.12%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ENMD-2076 Tartrate

Cat. No.: HY-10987

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC_{50}s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.



Purity: 98.87%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg

Glycyl H-1152 hydrochloride

Cat. No.: HY-15720B

Glycyl H-1152 hydrochloride (compound 18) is a glycyl derivative of Rho-kinase inhibitors H-1152 dihydrochloride. Glycyl H-1152 hydrochloride inhibits **ROCKII**, **Aurora A**, **CAMKII** and **PKG**, with IC_{50}s of 0.0118, 2.35, 2.57 and 3.26 μM respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

GSK-1070916

(GSK-1070916A)

Cat. No.: HY-70044

GSK-1070916 is a potent and selective ATP-competitive inhibitor of **aurora B** and **aurora C** with K_is of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.



Purity: 99.55%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

GW779439X

Cat. No.: HY-103645

GW779439X is a pyrazolopyridazine identified in an inhibitor of the S. aureus PASTA kinase **Stk1**. GW779439X potentiates the activity of β-lactam antibiotics against various MRSA and MSSA isolates, some even crossing the breakpoint from resistant to sensitive.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg

Hesperadin

Cat. No.: HY-12054

Hesperadin is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin inhibits Aurora B with an IC_{50} of 250 nM. Hesperadin inhibits the growth of Trypanosoma brucei by blocking nuclear division and cytokinesis.



Purity: ≥98.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Hesperadin hydrochloride

Cat. No.: HY-12054A

Hesperadin hydrochloride is an ATP competitive indolinone inhibitor of **Aurora A** and **B**. Hesperadin hydrochloride inhibits Aurora B with an IC_{50} of 250 nM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ilorasertib

(ABT-348)

Cat. No.: HY-16018

Ilorasertib (ABT-348) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: ≥98.0%
Clinical Data: Phase 2
Size: 50 mg, 100 mg

Ilorasertib hydrochloride

(ABT-348 hydrochloride)

Cat. No.: HY-16018A

Ilorasertib (ABT-348 hydrochloride) is a potent and ATP-competitive multitargeted kinase inhibitor, which inhibits **Aurora C**, **Aurora B**, and **Aurora A** with IC_{50}s of 1 nM, 7 nM, 120 nM, respectively.



Purity: 99.67%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

JB170

Cat. No.: HY-141512

JB170 is a potent and highly specific **PROTAC**-mediated **AURORA-A** (**Aurora Kinase**) degrader (DC_{50}=28 nM) by linking Alisertib, to the **Cereblon**-binding molecule Thalidomide. JB170 preferentially binds AURORA-A (EC_{50}=193 nM) over AURORA-B (EC_{50}=1.4 μM).



Purity: 98.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-7706621

Cat. No.: HY-10329

JNJ-7706621 is a potent **aurora kinase** inhibitor, and also inhibits **CDK1** and **CDK2**, with IC_{50}s of 9 nM, 3 nM, 11 nM, and 15 nM for **CDK1**, **CDK2**, **aurora-A** and **aurora-B**, respectively.



Purity: 99.96%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

KW-2449

Cat. No.: HY-10339

KW-2449 is a multi-targeted kinase inhibitor of **FLT3**, **ABL**, **ABL**^{T315I} and **Aurora kinase** with IC_{50}s of 6.6, 14, 4 and 48 nM, respectively.



Purity: 99.85%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

LY3295668

(AK-01)

Cat. No.: HY-114258

LY3295668 (AK-01) is a potent, orally active and highly specific **Aurora-A kinase** inhibitor, with K_i values of 0.8 nM and 1038 nM for AurA and AurB, respectively.



Purity: 98.88%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg

MK-5108

(VX-689)

Cat. No.: HY-13252

MK-5108 is a highly potent and specific inhibitor of **Aurora A kinase** with an IC_{50} value of 0.064 nM.



Purity: 99.89%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK-8745

Cat. No.: HY-13819

MK-8745 is an **aurora A** kinase inhibitor with an IC_{50} of 0.6 nM.



Purity: 99.49%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

MLN8054

Cat. No.: HY-10180

MLN8054 is a potent, selective and orally available **aurora A** kinase inhibitor with an IC_{50} of 4 nM.



Purity: 99.43%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

NU6140

Cat. No.: HY-107419

NU6140 is a selective **CDK2-cyclin A** inhibitor (IC_{50}, 0.41 μM), exhibits 10- to 36-fold selectivity over other CDKs. NU6140 also potently inhibits **Aurora A** and **Aurora B**, with IC_{50}s of 67 and 35 nM, respectively. Enhances the apoptotic effect, with anti-cancer activity.



Purity: 99.51%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

PF 477736

(PF 00477736)

Cat. No.: HY-10032

PF 477736 (PF 00477736) is a potent, selective and ATP-competitive inhibitor of **Chk1**, with a K_i of 0.49 nM, it is also a **Chk2** inhibitor, with a K_i of 47 nM.



Purity: 99.21%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PF-03814735

Cat. No.: HY-14574

PF-03814735 is a potent, orally available, ATP-competitive and reversible **aurora A** and **aurora B** inhibitor with IC_{50}s of 0.8 and 0.5 nM, respectively.



Purity: 99.82%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

PHA-680632

Cat. No.: HY-10178

PHA-680632 is an **aurora** kinase inhibitor with IC_{50}s of 27, 135 and 120 nM for aurora A, B and C, respectively.



Purity: 98.48%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Phthalazinone pyrazole

Cat. No.: HY-12564

Phthalazinone pyrazole is a potent, selective, and orally active inhibitor of Aurora-A kinase with an IC_{50} of 0.031 μM. Phthalazinone pyrazole can arrests mitosis and subsequently inhibit tumor growth via apoptosis of proliferating cells.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Retreversine

Cat. No.: HY-113894

Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Reversine

Cat. No.: HY-14711

Reversine is a novel class of ATP-competitive **Aurora kinase** inhibitor with IC_{50}s of 400, 500 and 400 nM for **Aurora A**, **Aurora B** and **Aurora C**, respectively.



Purity: 99.40%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759

Cat. No.: HY-10482

SCH-1473759 is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 98.20%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg

SCH-1473759 hydrochloride

Cat. No.: HY-10483

SCH-1473759 hydrochloride is an **aurora** inhibitor with IC_{50}s of 4 and 13 nM for aurora A and B, respectively.



Purity: 99.79%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

SNS-314

Cat. No.: HY-108344

SNS-314 is a potent and selective **aurora** kinase inhibitor with IC_{50}s of 9, 31, and 6 nM for aurora A, B and C, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

SNS-314 mesylate

Cat. No.: HY-12003

SNS-314 mesylate is a potent and selective **aurora** kinase inhibitor with IC_{50}s of 9, 31, and 6 nM for aurora A, B and C, respectively.



Purity: 99.90%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

SP-96

Cat. No.: HY-131339

SP-96 is a highly potent, selective and non-ATP-competitive **Aurora B** (IC_{50}=0.316 nM) inhibitor and shows >2000 fold selectivity against FLT3 and KIT. SP-96 shows selective growth inhibition in NCI60 screening, incluing MDA-MD-468 (GI_{50}=107 nM).



Purity: 98.03%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TAK-632

Cat. No.: HY-15767

TAK-632 is a potent **pan-RAF** inhibitor with IC_{50} of 1.4, 2.4 and 8.3 nM for **CRAF**, **$BRAF^{V600E}$**, **$BRAF^{WT}$**, respectively.



Purity: 98.46%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

TAK-901

Cat. No.: HY-12201

TAK-901 is a multi-targeted **aurora** inhibitor with IC_{50}s of 21 and 15 nM for aurora A and B, respectively.



Purity: 99.80%
Clinical Data: Phase 1
Size: 5 mg, 10 mg, 50 mg, 100 mg

TAK-901-d3

Cat. No.: HY-12201S

TAK-901-d3 is the deuterium labeled TAK-901. TAK-901 is a multi-targeted **aurora** inhibitor with IC_{50}s of 21 and 15 nM for aurora A and B, respectively.



Purity: >98%
Clinical Data:
Size: 1 mg, 10 mg

TAS-119

Cat. No.: HY-137377

TAS-119 is a potent, selective and orally active **Aurora A** inhibitor with an IC_{50} of 1.0 nM. TAS-119 shows high selectivity for **Aurora A** over other protein kinases, including Aurora B (IC_{50} of 95 nM). TAS-119 has potent antitumor activites.



Purity: 98.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

TC-A 2317 hydrochloride

Cat. No.: HY-103266

TC-A 2317 hydrochloride is an orally active **Aurora A kinase** inhibitor (K_i=1.2 nM). TC-A 2317 hydrochloride exhibits excellent selectivity to Aurora B kinase (K_i=101 nM) and other 60 kinases, good cell permeability and good PK profile. Antitumor activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

TCS7010

Cat. No.: HY-70061

TCS7010 is a potent and highly selective **Aurora A** inhibitor with with an IC_{50} of 3.4 nM.



Purity: 99.22%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Tinengotinib

Cat. No.: HY-145601

Tinengotinib is the modulator of one or more protein kinases such as **Aurora** kinase and **VEGFR** kinase. Tinengotinib has the potential for the research of these kinase abnormalities diseases mediated, especially cancer-related diseases (extracted from patent WO2018108079A1).



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tozasertib

(VX 680; MK-0457)

Cat. No.: HY-10161

Tozasertib (VX 680; MK-0457) is an inhibitor of **Aurora A/B/C kinases** with K_is of 0.6, 18, 4.6 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg, 250 mg

Tripolin A

((E)-Tripolin A)

Cat. No.: HY-124330

Tripolin A ((E)-Tripolin A) is a specific non-ATP competitive **Aurora A kinase** inhibitor, with IC_{50} values of 1.5 μM and 7 μM for Aurora A and Aurora B, respectively.
.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

XL228

Cat. No.: HY-15749

XL228 is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.



Purity: 99.58%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

ZM-447439

Cat. No.: HY-10128

ZM-447439 is an **aurora** kinase inhibitor with IC_{50}s of 110 and 130 nM for aurora A and B, respectively.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg